Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

NCT05891821 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Balstilimab

Sponsor

Immune Oncology Research Institute

Collaborators

[object Object]